The Omalizumab (Xolair) Pharmacokinetic ELISA Kit is an advanced analytical tool designed to measure the concentration of omalizumab, a monoclonal antibody targeting IgE, in biological samples. This kit plays a crucial role in pharmacokinetic (PK) studies, therapeutic drug monitoring, and biosimilar development. Its high sensitivity and specificity enable precise quantification of omalizumab levels in serum or plasma, facilitating research and clinical decision-making.
What is Omalizumab (Xolair)?
Omalizumab, marketed under the brand name Xolair, is a recombinant humanized monoclonal antibody that binds to IgE. By preventing IgE from interacting with its receptor on mast cells and basophils, omalizumab reduces the release of inflammatory mediators. It is widely used in treating allergic asthma, chronic idiopathic urticaria, and other IgE-mediated conditions.
Applications of the Pharmacokinetic ELISA Kit
- Pharmacokinetic Studies
- Evaluate the absorption, distribution, metabolism, and excretion (ADME) of omalizumab.
- Generate concentration-time curves to optimize dosing regimens.
- Therapeutic Drug Monitoring (TDM)
- Monitor omalizumab levels in patients to ensure therapeutic efficacy and minimize adverse effects.
- Adjust dosing based on individual pharmacokinetics.
- Biosimilar Development
- Compare the pharmacokinetic profiles of omalizumab biosimilars to the originator drug.
- Support regulatory submissions with robust analytical data.
- Clinical Research
- Investigate the relationship between omalizumab levels and clinical outcomes in IgE-mediated diseases.
- Study its effects in off-label indications.
Key Features of the ELISA Kit
- High Sensitivity and Specificity
- Detects omalizumab concentrations as low as 10 ng/mL.
- Minimal cross-reactivity with other monoclonal antibodies or IgE.
- Ready-to-Use Format
- Pre-coated plates and optimized reagents simplify the workflow.
- Wide Sample Compatibility
- Validated for use with human serum and plasma samples.
- Reproducibility
- Ensures consistent and reliable results across multiple assays.
Technical Specifications
| Parameter | Details |
|---|---|
| Detection Range | 10–1000 ng/mL |
| Assay Sensitivity | ~10 ng/mL |
| Sample Volume Required | 50 µL per well |
| Assay Time | ~3 hours |
| Storage Conditions | 2–8°C |
| Cross-Reactivity | <1% with non-target proteins |
Assay Procedure
- Sample Preparation
- Dilute serum or plasma samples as per the kit instructions.
- Add samples to the pre-coated microplate.
- Incubation
- Incubate the plate with a detection antibody specific to omalizumab.
- Wash to remove unbound components.
- Signal Development
- Add substrate solution to develop color.
- Measure absorbance at the specified wavelength using a microplate reader.
- Quantification
- Compare sample absorbance with a standard calibration curve to determine omalizumab concentration.
Advantages of the Kit
- High Precision
- The kit ensures accurate measurement of omalizumab levels, even at low concentrations.
- User-Friendly Protocols
- Ready-to-use reagents and pre-coated plates reduce assay time and complexity.
- Cost-Effective
- Eliminates the need for expensive instruments or specialized training.
- Regulatory Compliance
Applications in Biosimilar Research
With increasing interest in omalizumab biosimilars, this ELISA kit is a valuable tool for:
- Comparative PK Studies: Demonstrating bioequivalence to Xolair.
- Immunogenicity Testing: Detecting anti-drug antibodies (ADAs) in biosimilar trials.
Refer to ClinicalTrials.gov for ongoing studies involving omalizumab biosimilars.
Integration in Therapeutic Drug Monitoring (TDM)
Benefits:
- Personalized Medicine: Tailoring doses based on individual PK profiles.
- Improved Outcomes: Ensuring sufficient drug levels to achieve therapeutic goals.
- Reduced Costs: Preventing underdosing or overdosing.
Refer to resources from the National Institutes of Health (NIH) for insights into TDM practices.
Regulatory and Forensic Standards
This kit aligns with international standards for analytical methods, including:
- FDA Bioanalytical Method Validation
Ensures assay reliability and reproducibility. - WHO Guidelines
Supports pharmacokinetic studies in global clinical trials.
Conclusion
The Omalizumab (Xolair) Pharmacokinetic ELISA Kit is a versatile, high-precision tool for researchers and clinicians. Its applications in pharmacokinetic studies, therapeutic drug monitoring, and biosimilar development make it an essential resource for advancing clinical and scientific understanding of omalizumab.
For additional details, visit trusted resources like the NIH, FDA, and EMA.